These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 27615411)

  • 61. Therapeutic Approach to Adult Fibrotic Lung Diseases.
    Adegunsoye A; Strek ME
    Chest; 2016 Dec; 150(6):1371-1386. PubMed ID: 27521738
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Mycophenolate mofetil therapy for rapidly progressive interstitial lung disease in a patient with clinically amyopathic dermatomyositis.
    Tsuchiya H; Tsuno H; Inoue M; Takahashi Y; Yamashita H; Kaneko H; Kano T; Mimori A
    Mod Rheumatol; 2014 Jul; 24(4):694-6. PubMed ID: 24506658
    [No Abstract]   [Full Text] [Related]  

  • 63. Open-label compassionate use one year-treatment with pirfenidone to patients with chronic pulmonary fibrosis.
    Nagai S; Hamada K; Shigematsu M; Taniyama M; Yamauchi S; Izumi T
    Intern Med; 2002 Dec; 41(12):1118-23. PubMed ID: 12521199
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Skin ulcer is a predictive and prognostic factor of acute or subacute interstitial lung disease in dermatomyositis.
    Ishigaki K; Maruyama J; Hagino N; Murota A; Takizawa Y; Nakashima R; Mimori T; Setoguchi K
    Rheumatol Int; 2013 Sep; 33(9):2381-9. PubMed ID: 23553518
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Successful delivery in a patient with clinically amyopathic dermatomyositis during pregnancy despite first-trimester acute exacerbation of interstitial lung disease.
    Ochiai M; Sato E; Tanaka E; Tochihara M; Shimizu Y; Osawa H; Sidara K; Sugimoto N; Hoshi D; Kawaguchi Y; Taniguchi A; Yamanaka H
    Mod Rheumatol; 2017 Mar; 27(2):364-368. PubMed ID: 25619281
    [TBL] [Abstract][Full Text] [Related]  

  • 66. [Therapeutic efficacy of cyclosporin A in four cases of amyopathic dermatomyositis with rapidly progressive interstitial pneumonia].
    Ozawa Y; Kurosaka D; Yokoyama T; Tajima N
    Ryumachi; 2000 Oct; 40(5):798-809. PubMed ID: 11215158
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Effects of pirfenidone on renal function in patients with interstitial pneumonia.
    Matsumoto J; Sunohara K; Mori Y; Nagaya H; Inaba S
    Ren Fail; 2021 Dec; 43(1):879-881. PubMed ID: 34018462
    [No Abstract]   [Full Text] [Related]  

  • 68. Safety and efficacy of pirfenidone in severe Idiopathic Pulmonary Fibrosis: A real-world observational study.
    Tzouvelekis A; Ntolios P; Karampitsakos T; Tzilas V; Anevlavis S; Bouros E; Steiropoulos P; Koulouris N; Stratakos G; Froudarakis M; Bouros D
    Pulm Pharmacol Ther; 2017 Oct; 46():48-53. PubMed ID: 28843616
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Interstitial lung disease related to dermatomyositis. Comparative study with patients without lung involvement.
    Grau JM; Miró O; Pedrol E; Casademont J; Masanés F; Herrero C; Haussman G; Urbano-Márquez A
    J Rheumatol; 1996 Nov; 23(11):1921-6. PubMed ID: 8923367
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Predictors of the clinical effects of pirfenidone on idiopathic pulmonary fibrosis.
    Arai T; Inoue Y; Sasaki Y; Tachibana K; Nakao K; Sugimoto C; Okuma T; Akira M; Kitaichi M; Hayashi S
    Respir Investig; 2014 Mar; 52(2):136-43. PubMed ID: 24636270
    [TBL] [Abstract][Full Text] [Related]  

  • 71. The long-term outcome of interstitial lung disease with anti-aminoacyl-tRNA synthetase antibodies.
    Tanizawa K; Handa T; Nakashima R; Kubo T; Hosono Y; Watanabe K; Aihara K; Ikezoe K; Sokai A; Nakatsuka Y; Taguchi Y; Hatta K; Noma S; Kobashi Y; Yoshizawa A; Oga T; Hirai T; Chin K; Nagai S; Izumi T; Mimori T; Mishima M
    Respir Med; 2017 Jun; 127():57-64. PubMed ID: 28461123
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Association of anti-aminoacyl-transfer RNA synthetase antibody and anti-melanoma differentiation-associated gene 5 antibody with the therapeutic response of polymyositis/dermatomyositis-associated interstitial lung disease.
    Yoshida N; Okamoto M; Kaieda S; Fujimoto K; Ebata T; Tajiri M; Nakamura M; Tominaga M; Wakasugi D; Kawayama T; Kuwana M; Mimori T; Ida H; Hoshino T
    Respir Investig; 2017 Jan; 55(1):24-32. PubMed ID: 28012490
    [TBL] [Abstract][Full Text] [Related]  

  • 73. [The predictive factors and unfavourable prognostic factors of interstitial lung disease in patients with polymyositis/dermatomyositis].
    Wang PZ; Guan JL; Han XH
    Zhonghua Jie He He Hu Xi Za Zhi; 2008 Jun; 31(6):417-20. PubMed ID: 19031800
    [TBL] [Abstract][Full Text] [Related]  

  • 74. [Clinical analysis of 29 patients with clinically amyopathic dermatomyositis].
    Zhang ZL; Lai AY; Xu D; Chen YH; Tang FL
    Zhonghua Yi Xue Za Zhi; 2007 May; 87(19):1345-7. PubMed ID: 17727782
    [TBL] [Abstract][Full Text] [Related]  

  • 75. High-resolution computed tomography characterization of interstitial lung diseases in polymyositis/dermatomyositis.
    Hayashi S; Tanaka M; Kobayashi H; Nakazono T; Satoh T; Fukuno Y; Aragane N; Tada Y; Koarada S; Ohta A; Nagasawa K
    J Rheumatol; 2008 Feb; 35(2):260-9. PubMed ID: 18085731
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Successful treatment of dermatomyositis-related rapidly progressive interstitial pneumonitis with sequential oral cyclophosphamide and azathioprine.
    Mok CC; To CH; Szeto ML
    Scand J Rheumatol; 2003; 32(3):181-3. PubMed ID: 12892257
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Efficacy of infliximab in the treatment for dermatomyositis with acute interstitial pneumonia: a study of fourteen cases and literature review.
    Chen D; Wang XB; Zhou Y; Zhu XC
    Rheumatol Int; 2013 Oct; 33(10):2455-8. PubMed ID: 23715693
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Fatal rapidly progressive interstitial pneumonitis associated with amyopathic dermatomyositis and CD8 T lymphocytes.
    Yokoyama T; Sakamoto T; Shida N; Kinoshita M; Kunou Y; Karukaya R; Takamatsu M; Aizawa H
    J Intensive Care Med; 2005; 20(3):160-3. PubMed ID: 15888904
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Safety and efficacy of pirfenidone in idiopathic pulmonary fibrosis in clinical practice.
    Okuda R; Hagiwara E; Baba T; Kitamura H; Kato T; Ogura T
    Respir Med; 2013 Sep; 107(9):1431-7. PubMed ID: 23849626
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Effect of Perioperative Pirfenidone Treatment in Lung Cancer Patients With Idiopathic Pulmonary Fibrosis.
    Iwata T; Yoshida S; Fujiwara T; Wada H; Nakajima T; Suzuki H; Yoshino I
    Ann Thorac Surg; 2016 Dec; 102(6):1905-1910. PubMed ID: 27546601
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.